Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top California based Vice President operating in the Health Care space. If you think a Vice President is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Emily Reuter
Vice President of Strategy and Operations of Color
Emily Reuter is the Vice President of Strategy and Operations at Color.
Follow Emily Reuter:
About Color: Color is a population health technology company that enables the delivery of advanced healthcare through clinical genetics.
Jeff Birkeland
Vice President of Product, Consumer Experience of Headspace
director of product @ facebook video focused on building for creators and publishers. formerly led the Feed team at LinkedIn. Before that built a publishing startup, and multiple news and media products at Yahoo! former television producer. drinks coffee. bald.
Follow Jeff Birkeland:
About Headspace, High Gear Media, LinkedIn: Headspace is a digital health platform that provides guided meditation sessions and mindfulness training.
Kris Snodgrass
Vice President of Talent of Norwest Venture Partners
Follow Kris Snodgrass:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Ellie Javadi
Vice President | Head of Communications, PR, Marketing of Norwest Venture Partners
Follow Ellie Javadi:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Raymond H. Diradoorian
Executive Vice President of Allergan
Mr. Diradoorian has been Executive Vice President, Global Technical Operations since February 2006. From April 2005 to February 2006, Mr. Diradoorian served as Senior Vice President, Global Technical Operations. Since February 2001, Mr. Diradoorian served as Vice President, Global Engineering and Technology. Mr. Diradoorian joined Allergan in July 1981. Prior to joining Allergan, Mr. Diradoorian held positions at American Hospital Supply and with the Los Angeles Dodgers baseball team. Mr. Diradoorian received a Bachelor of Science degree in Biological Sciences from the University of California, Irvine and a Master of Science degree in Technology Management from Pepperdine University.
Follow Raymond H. Diradoorian:
About Allergan: Allergan is a global pharmaceutical company.
Ronald Hutton
Vice President, Treasurer of Bio-Rad Laboratories
Follow Ronald Hutton:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
James Stark
Vice President, Corporate Controller of Bio-Rad Laboratories
Follow James Stark:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Mike Crowley
Executive Vice President, Global Commercial Operations of Bio-Rad Laboratories
Follow Mike Crowley:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Timothy Ernst
Executive Vice President, General Counsel & Secretary of Bio-Rad Laboratories
Follow Timothy Ernst:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Rachel Gollub
Vice President of Benefitter Technology of UnitedHealth Group
Founder at Benefitter
Follow Rachel Gollub:
About Benefitter, HealthMarkets, UnitedHealth Group: UnitedHealth Group is a healthcare company that offers insurance products and services for everyone.
Maynd Jolly
Vice President Strategic Corporate Accounts of Siemens Healthineers
Follow Maynd Jolly:
About Siemens Healthineers: Siemens Healthineers is a healthcare technology company that provides diagnostic and therapeutic products and services.
Chris Fuller
Vice President of Informatics of Caribou Biosciences
Follow Chris Fuller:
About Caribou Biosciences: Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Alex Aravanis
Chief Technology Officer & Senior Vice President of Illumina
Follow Alex Aravanis:
About Illumina: Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Craig Ciesla
Vice President Advanced Engineering of Illumina
Follow Craig Ciesla:
About Illumina: Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Richard Klausner
Senior Vice President & Chief Medical Officer of Illumina
Richard Klausner joined Illumina in September 2013 as Senior Vice President and Chief Medical Officer. Richard is responsible for Illumina’s strategies for advancing genomics into clinical medicine and public health. He is also part of Illumina’s executive management team, which is responsible for directing all aspects of company strategy, planning and operations. Richard is a Scientific Advisor at Cyterix Pharmaceuticals Inc. He co-founded Pathwork Diagnostics, Inc. (Alternative name is Predicant Biosciences Inc.) in 2002. He serves as the Managing Partner at The Column Group LLC. He served as the Chairman of the Strategic Development and Scientific Advisory Council at Sanofi from March 1, 2011 to January 2013. Richard serves as the Chairman of the National Science Education Standards Projects of the National Academy of Science, overseeing the first comprehensive process to provide a vision of scientific literacy in the American educational system and the criteria required to achieve it. He served as Co-Chairman of the Scientific Advisory Board and Scientific Advisor at Aragon Pharmaceuticals, Inc. He served as an Executive Director for Global Health at the Bill & Melinda Gates Foundation. Richard served as the President at the American Society of Clinical Investigation. He served as an Advisor to the President of the Academies for counter-terrorism, and a Liaison to the White House Office of Science and Technology Policy. From 1979 to 1981, he worked at NIH in National Cancer Institute’s (NCI) Laboratory of Mathematical Biology. He served as a Director of Pathwork Diagnostics, Inc. and Immune Design Corp. He served as Director of 3-V Biosciences, Inc. He served as a Director of NCI from August 1, 1995 to 2001. He serves as a Member of Scientific Advisory Board at NGM Biopharmaceuticals, Inc., Immune Design Corp., Constellation Pharmaceuticals and Audax Health Solutions. Richard served as a Distinguished Scientific and Strategic Advisor of Aveo Pharmaceuticals, Inc. Richard currently sits on the board of Juno Therapeutics. He is also the Chief Strategy Advisor for USAID. He is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. He served as a Member of Scientific Advisory Board at Infinity Pharmaceuticals, Inc., Igenica, Inc. and T2 Biosystems, Inc. Rick holds an M.D. from Duke Medical School.
Follow Richard Klausner:
About Audax Health Solutions, Illumina, Pathwork Diagnostics: Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Austin Harkness
Executive Vice President, Operations of Honor
Follow Austin Harkness:
About Honor, Sunoco – Stores: Honor is a senior care network and technology platform that offers personalized care to improve the in-home care experience.
Andy Iseli
Vice President and General Manager, CCL Tube of CCL Industries
Andy Iseli is a Vice President and General Manager, CCL Tube at CCL Industries.
Follow Andy Iseli:
About CCL Industries: CCL is the largest label company in the world and provides innovative solutions.
Agatha Martindale
Vice President and Global Finance of Rakuten Medical
Follow Agatha Martindale:
About BUILTBYGIRLS, Rakuten Medical, Rakuten Medical: Rakuten Medical is a biotechnology company that develops therapies to treat cancer.
Helene Klein
Executive-Vice President, People of Beachbody
Follow Helene Klein:
About Beachbody: Beachbody has developed and offering an in-home fitness and weight loss solutions.
Hartmuth Kolb
Vice President, Neuroscience Biomarkers and Janssen R&D Global Imaging of Johnson & Johnson
Follow Hartmuth Kolb:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Asish Xavier
Vice President, Venture Investments of Johnson & Johnson Development Corporation
Asish Xavier is the Vice President of Venture Investments at joined Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 2004. Asish is based in Silicon Valley, California. Asish previously worked in business development at BioRexis Pharmaceutical, Inc., which was acquired by Pfizer in 2007. While at BioRexis, Asish assisted the company in raising a $30 million second round of financing. Asish has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc. Asish received a Ph.D. from the University of Houston and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he graduated with honors. Asish received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. Asish was also a postdoctoral research Fellow in the Department of Chemistry at Johns Hopkins University.
Follow Asish Xavier:
About Cue, ESCAPE Bio, Johnson & Johnson Development Corporation, Legend Biotech, Paige, ViaCyte, XWPharma: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Stacy Feld
Vice President, Consumer Venture Investments of Johnson & Johnson Development Corporation
Stacy received a B.A. in sociology, graduating magna cum laude from the University of Pennsylvania and earned her J.D. from Vanderbilt Law School.
Follow Stacy Feld:
About Johnson & Johnson Development Corporation, Johnson & Johnson Development Corporation: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Albert Chan
Enterprise Vice President, Chief of Digital Patient Experience of Sutter Health
Albert Chan, M.D., M.S., FAAFP, as Vice President, Chief of Digital Patient Experience at Sutter Health, is the corporate champion for the transformation of web and mobile health care services, translating the latest advancements in digital health into consumer-centric patient experiences and digitally empowered clinician workflows. He also leads the Sutter Health My Health Online initiative. He practices in Family Medicine at the Palo Alto Medical Foundation. He earned a bachelor’s degree with honors in Biological Sciences from Stanford University and a medical degree from the University of California, San Diego School of Medicine. He completed his residency and year as chief resident in family medicine at the San Jose Medical Center Family Practice Residency, affiliated with Stanford University of School of Medicine. He concurrently completed a postdoctoral fellowship in Biomedical Informatics at Stanford University School of Medicine and Family Medicine Research at the University of California, San Francisco School of Medicine, studying the effects of point of care decision support in the management of hypertension. During fellowship, Dr. Chan also assisted with the launch of PAMFOnline, now Sutter’s My Health Online, one of the earliest PHRs in the United States.
Follow Albert Chan:
About Sutter Health: Sutter Health is a non-profit organization operating a network of hospitals and physicians in Northern California.
Hakan Sakul
Vice President and Head of Diagnostics of Pfizer
Follow Hakan Sakul:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Bob Colloton
Vice President of Sales & Marketing of Neuravi
Follow Bob Colloton:
About MIVI Neuroscience, Neuravi: Neuravi provides medical products and services.
Joshua Sommerfeld
Vice President of Redmile Group
Josh is a member of the investment team at Redmile Group. Prior to Redmile, Josh was Director of Operations at Stride Health, where he built the company’s sales, customer support, regulatory, and data operations teams. Prior to Stride Health, Josh was the lead Associate for Bain Capital Venture’s early-stage and growth equity activity in the healthcare vertical, where he focused on healthcare IT and healthcare services. Companies in Josh’s portfolio included Liazon (sold to Tower’s Watson) and National Cardiovascular Partners (sold to Fresenius). Josh began his career as a management consultant at Bain & Company in Chicago and Melbourne, Australia. Josh graduated with honors from University of Chicago where he received a BA in South Asian Languages and Civilizations.
Follow Joshua Sommerfeld:
About Redmile Group, Wellington Management: Redmile Group is a healthcare investment organization that makes venture, growth, and crossover investing across healthcare.
Steve Pham
Vice President of Clinical and Research Affairs of Eko Health
Steve Pham is a practicing emergency medicine physician, the head of medical and research affairs at Eko, and a new father. His passion is translating between digital and clinical insights.
Follow Steve Pham:
About Eko Health: Eko develops AI-powered digital tools to detect and monitor heart and lung disease
Gene Hung
Co-founder and Senior Vice President of XinThera
Gene Hung is a Co-founder and Senior Vice President at Xinthera Inc.
Follow Gene Hung:
About XinThera: XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Kathryn E. Falberg
Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals
Kathryn Falberg was appointed our Executive Vice President and Chief Financial Officer in March 2012. She served as our Senior Vice President and Chief Financial Officer from 2009 to 2012. Her responsibilities include finance, strategy, corporate development and IT. From 1995 through 2001, Kathryn Falberg was with Amgen, Inc., where she served as Senior Vice President Finance, Strategy and Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. From 2001 through 2008, Kathryn Falberg was President of Canyon Capital & Consulting, a private investment and consulting firm, where she worked with a number of smaller companies while also serving as a corporate director and audit committee chair for several companies. From February to November 2009, she was Chief Financial Officer and Chief Operating Officer at ARCA biopharma, Inc., a biopharmaceutical company. Kathryn Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant (inactive). Kathryn Falberg currently serves on the boards, and is chair of the audit committees, of biopharmaceutical companies Halozyme Therapeutics, Inc. and Medivation, Inc.
Follow Kathryn E. Falberg:
About Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments.
Robert Desantis
Executive Vice President Chief Product Officer of Intuitive Surgical
Bob DeSantis joined Intuitive Surgical in January 2013 as Vice President, Research and Development, Instruments and Accessories Engineering. In November 2015, Mr. DeSantis was promoted to the position of Senior Vice President, Instruments and Accessories. In this position, Mr. DeSantis is responsible for managing the development of new technology from design to market as well as production engineering support for the instrument and accessory portfolio. Prior to joining Intuitive Surgical, Mr. DeSantis spent almost twenty years in the medical device industry, holding positions at several companies, including US Surgical and most recently at Covidien, where he last served as the Vice President, Research and Development for the mechanical and energy instrument businesses. Mr. DeSantis holds a B.S. and M.S.in Mechanical Engineering from the State University of New York at Buffalo. Mr. DeSantis also holds a certificate in Innovation Management from MIT.
Follow Robert Desantis:
About Intuitive Surgical: The da Vinci Surgical System is changing the experience of surgery for patients around the world.
Dave Rosa
Executive Vice President & Chief Business Officer of Intuitive Surgical
Dave J. Rosa joined Intuitive Surgical in March 1996 and has held leadership positions in Engineering, Clinical Development, Marketing and Product Development. In 2015, Mr. Rosa was appointed as Executive Vice President and Chief Commercial Officer. In 2013, Mr. Rosa assumed the position of Senior Vice President, Scientific Affairs and, in 2014, he was appointed as Executive Vice President and Chief Scientific Officer. He has been a passionate supporter and evangelist of da Vinci technology since its inception. Prior to joining Intuitive Surgical, Mr. Rosa contributed to the development of trans-esophageal transducers for Acuson Corporation. He graduated magna cum laude with a B.S.in Mechanical Engineering from California Polytechnic University at San Luis Obispo. He also holds a M.S. in Mechanical Engineering from Stanford University.
Follow Dave Rosa:
About Intuitive Surgical: The da Vinci Surgical System is changing the experience of surgery for patients around the world.
Gillian Duncan
Senior Vice President, Professional Education & Program Services – Worldwide of Intuitive Surgical
Gillian Duncan, Ed.D., joined Intuitive Surgical in December 2006 as an Education Manager. After holding several positions of increasing responsibility in clinical, product and professional education, Dr. Duncan was promoted to the position of Vice President, da Vinci® Professional Education & Program Services – Worldwide in August 2015. In this role, Dr. Duncan is responsible for leading the company’s high-quality, worldwide Customer Training, Genesis, Lab Services and Clinical and Product Education programs. Prior to joining Intuitive Surgical, Dr. Duncan held both teaching and research positions at Columbia University and California State University, East Bay. Dr. Duncan holds a B.A. in Rhetoric from the University of California, Berkeley, and master’s and doctorate degrees in Applied Physiology from Columbia University.
Follow Gillian Duncan:
About Intuitive Surgical: The da Vinci Surgical System is changing the experience of surgery for patients around the world.
Myriam Curet
Executive Vice President & Chief Medical Officer of Intuitive Surgical
Myriam J. Curet, M.D. joined Intuitive Surgical in December 2005, as Chief Medical Advisor. In February 2014, Dr. Curet was promoted to the position of Chief Medical Officer. Dr. Curet also held a faculty position as Professor of Surgery at Stanford University. Since October 2010, she has served as a Consulting Professor of Surgery at Stanford University with a part time clinical appointment at the Palo Alto Veteran’s Administration Medical Center. Dr. Curet received her M.D. from Harvard Medical School and completed her general surgery residency program at the University of Chicago. She then worked for the Indian Health Service for four years before finishing her Surgical Endoscopy fellowship at the University of New Mexico. She was on the faculty at the University of New Mexico for six years prior to joining the Stanford University Department of Surgery in 2000.
Follow Myriam Curet:
About Intuitive Surgical: The da Vinci Surgical System is changing the experience of surgery for patients around the world.
Craig Child
Sr. Vice President, Human Resources of Intuitive Surgical
Craig Child joined Intuitive Surgical in May 2001 as a Recruiting Consultant. In March 2015, Craig Child was promoted to the position of Vice President, Human Resources. Prior to this role, Mr. Child has held several key positions since the inception of the human resources organization at Intuitive Surgical, playing an instrumental role in the development of key human resources functions. Prior to joining Intuitive Surgical, Mr. Child held positions in human resources at Adobe and Informix. Mr. Child holds a B.A. in Psychology from the University of Oregon and a M.B.A from Colorado State University.
Follow Craig Child:
About Intuitive Surgical: The da Vinci Surgical System is changing the experience of surgery for patients around the world.
Charles Jones
Senior Vice President, Design and User Experience of Intuitive Surgical
Charles Jones joined Intuitive Surgical in April 2016 as the Senior Vice President, Design and User Experience. In this role, Mr. Jones is responsible for leading the company’s efforts to blend leading-edge technology with enhanced human-centered design thinking and driving a consistent design experience for Intuitive products and services. Prior to joining Intuitive Surgical, Mr. Jones has held several key leadership roles at Whirlpool Corp., Xerox Corp. and Herman Miller, and most recently served as the Chief Design and Technology Officer for Newell Rubbermaid. Mr. Jones has received several international design awards, including the prestigious Smithsonian National Design Award, and holds several patents. Mr. Jones is an honors graduate from Purdue University with degrees in Industrial Design and Human Factors Engineering.
Follow Charles Jones:
About Intuitive Surgical: The da Vinci Surgical System is changing the experience of surgery for patients around the world.
James Hinrichs
Executive Vice President and Chief Financial Officer of Alere
James (“Jim”) Hinrichs joined Alere in April 2015 as Executive Vice President and Chief Financial Officer, with global responsibility for Finance, Accounting, Procurement, IT and Shared Services. Prior to his appointment as CFO of Alere, Jim Hinrichs was CFO at CareFusion Corp., a global medical technology corporation, since 2010. He held this position through the completion of Becton Dickinson’s acquisition of CareFusion in March 2015. Prior to this role, Hinrichs served as SVP of Global Customer Support and, before that, Corporate Controller of CareFusion. Previously, he was Executive Vice president and Controller of Cardinal Health, CFO of Cardinal Health’s Clinical and Medical Products segment and CFO of Cardinal Health’s Healthcare Supply Chain Services segment.. He joined Cardinal Health in February 2004, following 12 years of finance and marketing roles at Merck & Co. and two years as the CFO of SangStat Medical Corporation.
Follow James Hinrichs:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Mark Gladwell
Senior Vice President, Global Operations of Alere
Mark Gladwell has served as Senior Vice President, Global Operations since January 2015. From January 2014 through January 2015, he held the role of Vice President, Operations for North America, Europe, Middle East and Africa. From September 2011 through December 2013, Mr. Gladwell served as Vice President of Operations for North America and as President and General Manager of one of Alere’s key manufacturing facilities in North America. From 2007 to 2010 Mr. Gladwell was Vice President, Quality and Technical Service for Alere. From 2005 to 2007, he served as a director covering multiple functions in the start-up of Alere Technology Limited where he focused on the development and manufacture of the Alere home BNP product. Prior to 2005 Mr. Gladwell held a variety of operations, quality and project leadership positions in North America and Europe for Alere, Johnson & Johnson, Agfa Gavert and DuPont. Mr. Gladwell has more than 18 years of experience in manufacturing high-volume, high-technology in-vitro diagnostics and medical devices.
Follow Mark Gladwell:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Charles Yang
Vice President of Quality Assurance & Regulatory Affairs of Blockade Medical
Charles is currently the Vice President of Quality Assurance and Regulatory Affairs at Blockade Medical. He has been in the medical device industry for over 15 years in the quality and regulatory field with extensive experience in achieving product approvals in a timely manner. Charles has been successful in achieving multiple product approvals through CE Mark, 510K and other regulatory processes all over the world. He has a diversified portfolio of working in start-up companies and large corporations which has allowed him to gain the experience to build efficient quality systems that meet the needs of the medical device industry. Prior to joining Blockade Medical, Charles worked at various medical device companies which include Acutus Medical, MindFrame Inc. (acquired by Covidien), Ablation Frontiers (acquired by Medtronic) and Edwards LifeSciences. Charles received a B.S. in Bio-engineering at the University of California, San Diego.
Follow Charles Yang:
About Blockade Medical: Founded in 2011, Blockade Medical is a privately held company dedicated the development of catheter based therapeutic devices for the
Ryan Solomon
Vice President of Marketing & Business Development of Blockade Medical
Ryan is the Director of Global Marketing and Business Development at Blockade Medical and has more than 10 years of medical sales and marketing expertise including extensive interventional neurovascular experience. Ryan has successfully launched many products in the neurovascular field including launching the first flow diversion device in the United States while serving as the Group Marketing Manager at Covidien Neurovascular and global launches of multiple coil lines as a Sr. Product Manager at MicroVention. His previous roles have also included Associate Marketing Manager at Karl Storz Endoscopy, Sr. Clinical Sales Specialist at Glaxo Smith Kline, and a Professional Sales Representative for Boehringer Ingelheim. Ryan received a B.S. in Business Administration from the University of California, Riverside and a M.B.A. from the University of California, Irvine.
Follow Ryan Solomon:
About Blockade Medical: Founded in 2011, Blockade Medical is a privately held company dedicated the development of catheter based therapeutic devices for the
Bhavin Shah
Vice President of Engineering and Quality of Paramit Corporation
Bhavin joined Paramit in 2014. Bhavin brings with him over 20 years of experience in developing products involving hardware and software/firmware for multiple industries. Prior to Paramit, Bhavin spent 5 years at Diamond Systems, managing engineering teams developing high precision digital and analog PCBAs and 9+ years with Asyst Technologies. Bhavin has a BSEE from the Mumbai University(India) and a Post Graduate Diploma in Advanced Computing from C-DAC (India).
Follow Bhavin Shah:
About Paramit Corporation: Paramit designs and manufactures medical devices and life science instruments.
Francesco Grieco
Vice President of Operations of Paramit Corporation
Francesco Grieco is the VP of Operations at Paramit Corporation.
Follow Francesco Grieco:
About Paramit Corporation: Paramit designs and manufactures medical devices and life science instruments.
Ed Chuang
Vice President, Marketing and Business Development of ClearCare
Follow Ed Chuang:
About ClearCare: ClearCare is a web-based software solution that helps home care agencies efficiently focus on what’s important: providing better care.
Thomas Alessi
Vice President, Development and Manufacturing of Intarcia Therapeutics
Dr. Alessi joined Intarcia in December 1997 as Executive Director, Regulatory Affairs and Drug Development and was promoted to Vice President, Development in February 2002 with responsibility for the areas of product development, project management, chemistry and manufacturing. Prior to joining Intarcia, Dr. Alessi served as the Senior Director, Regulatory Affairs, Quality Assurance and Project Management at Ansan Pharmaceuticals where he was responsible for successful IND filings and for managing five drug development programs with oversight of vendors for preclinical and clinical studies and manufacturing clinical supplies. Before joining Ansan, Dr. Alessi was Director of Regulatory Affairs and Quality Assurance at Glycomed, Inc. where his duties included oversight and compliance of clinical manufacturing. His previous experience includes regulatory affairs and drug discovery experience in large pharmaceutical companies. Dr. Alessi was Senior Manager of Regulatory Affairs for Schering-Plough working in the Anti-infectives, Allergy Products and Chemisty, Manufacturing, & Controls groups. While at Schering-Plough, Dr. Alessi had regulatory responsibilities for approval and launch of interferon alfa-2b for hepatitis C as well as for hepatitis B. In his CMC role, he served on separate committees for process development and production of solid oral dosage forms, inhaled products, creams and semisolid products and sterile dosage forms, in addition to regulatory review of the CMC sections of Schering-Plough INDs and NDAs. Prior to joining Schering-Plough, Dr. Alessi invented and patented several new families of antidiabetic drugs while working as a Senior Scientist in the drug discovery group at Wyeth-Ayerst. Dr. Alessi earned a B.S. degree at Allegheny College and an M.S. and a Ph.D. in organic synthetic chemistry from the University of Rochester.
Follow Thomas Alessi:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Paul Negulescu
Vice President of Vertex Pharmaceuticals
Paul Negulescu is the Senior Vice President and Site Head of San Diego Research. He’s been leading Vertex’s San Diego research location since 2003, the site that discovered Vertex’s medicines that treat the underlying cause of cystic fibrosis. Prior to joining Vertex, Dr. Negulescu was Senior Vice President of Discovery Biology and a member of the executive team at Aurora Biosciences. When Vertex acquired Aurora, he was responsible for integrating Aurora’s research into Vertex. Dr. Negulescu received both his B.S. and Ph.D. from U.C. Berkeley in Physiology and carried out post-doctoral work at U.C. Berkeley and U.C. Irvine in the areas of ion channel biophysics and immunology.
Follow Paul Negulescu:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Glenn S. Boehnlein
Chief Financial Officer & Vice President of Stryker
Follow Glenn S. Boehnlein:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Shian-Jiun Shih
Vice President of Product Development of Tessa Therapeutics
Dr. Shih has over 20 years of experience in the biopharmaceutical industry, with strong expertise in biological drug development, including cell and gene therapy products and therapeutic proteins, with a focus on immunotherapy. Prior to joining Tessa, she was Director of Molecular Biomarkers and Site Lead of the Translational Medicine and Research Centre, Merck Sharp & Dohme. In that role, her group established non-human primate disease models and developed clinical biomarker assays to support early phase clinical trials, including those for Keytruda. Before that she was Director, Assay Development, Cell Genesys, Inc. She has also held various roles in Bayer, Aventis, and Applied Immune Sciences. Dr. Shih is Founding President of the Chinese Bioscience Association. She holds a Ph.D. in Biochemistry from University of Wisconsin at Madison and completed her post-doctoral training at the School of Medicine, Stanford University.
Follow Shian-Jiun Shih:
About Tessa Therapeutics: Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors.
Darren Hudgins
Vice President, Software Engineering of Breathometer
Darren Hudgins is the Vice President, Research & Development of Hillrom.
Follow Darren Hudgins:
About Breathometer, Hill-Rom: Breathometer develops a breath analysis technology that helps people make smarter decisions and improve their lives.
Heather A. Brown
Senior Vice President, Market Access & Reimbursement of HeartFlow
Dr. Brown brings 10 years of experience in advanced medical imaging product development and service. She has held leadership roles in multiple startups and drove the development of AAA stent graft and TAVR planning applications as well as novel methods of assessing cardiac wall mechanics. Dr. Brown developed the first Volumetric Medical Imaging college accredited program at Jefferson Community and Technical College in 2005. She holds six patents. She received her B.S. degree in Mechanical Engineering from Michigan Technological University, and M.S. and Ph.D. degrees in Biomedical Engineering from Vanderbilt University.
Follow Heather A. Brown:
About HeartFlow: HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease.
Lara Abbaschian
Vice President of Lightstone Ventures
Follow Lara Abbaschian:
About Lightstone Ventures: Lightstone Ventures is a leading global venture capital firm.
Jennifer Carter
Vice President, Portfolio Development of McKesson Ventures
Jennifer Carter is the Vice President of Portfolio Development for McKesson Ventures. Jennifer works closely with portfolio companies to help identify and evaluate synergies across the McKesson ecosystem, which includes McKesson’s business units, customers and employee base. In addition, when these synergies create mutual value she helps facilitate efficient execution by acting as a liaison or project manager in order to ensure McKesson Ventures lives up to its value proposition. Jennifer brings over 15 years of experience from various roles across the McKesson enterprise. Jennifer holds a B.S. in Economics from Boston College. Although born and raised in San Francisco, Jennifer spends harvest season on the family farm cultivating pluots and disrupting the plum and apricot industries.
Follow Jennifer Carter:
About McKesson Ventures, McKesson Ventures: McKesson Ventures is a California-based venture capital that focuses on the healthcare industry.
Curtis Scribner
Vice President, Regulatory of Eiger BioPharmaceuticals
Dr. Scribner has more than 25 years of drug development and regulatory affairs experience. He spent 11 years at the FDA in the Center for Biologics as a medical officer with wide experience reviewing non-clinical, CMC, clinical, and IND/BLA regulatory systems, including 2.5 years as the Deputy Director of the Office of Blood. He also was the Senior Regulatory Consultant for Quintiles Consulting, Chief Regulatory Office for Intarcia Therapeutics and he is now the Senior Vice President for Medical and Regulatory Affairs for RRD International. Dr. Scribner is a board certified Internist with post-doctorial training in Immunology and Rheumatology at the NIH.
Follow Curtis Scribner:
About Eiger BioPharmaceuticals, QED Therapeutics: Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.
Kevin Kaster
Vice President, Patents and Licensing of Eiger BioPharmaceuticals
Kevin Kaster has 20 years of experience in biotechnology and large pharma with an established track record of developing effective patent and licensing strategies for important technologies and drug products.Kevin Kaster most recently served as Vice President Corporate Development for Threshold Pharmaceuticals, a public company focused on developing anti-cancer agents. Previously, Kaster was Vice President Intellectual Property for Kosan Biosciences, a public company acquired by BMS in 2008 with geldanamycin and epothilone anti-cancer agents. Kaster also previously managed the patent portfolios of Geron Corporation (telomerase and human embryonic stem cell technologies) and Affymax/Affymetrix (combinatorial chemistry and DNA chip technologies) as well as the PCR technology patent portfolio of Cetus Corporation. Kaster began his career at Eli Lilly and Company, first as a research scientist and then as a patent technician.Kevin Kaster is a graduate of the Indiana University School of Law and a graduate of Vanderbilt University with a BS in Chemistry and Molecular Biology.
Follow Kevin Kaster:
About Eiger BioPharmaceuticals, Lygos: Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.
Shelly Xiong
Vice President, Regulatory Affairs of Eiger BioPharmaceuticals
Shelly Xiong has over 20 years of pharmaceutical industry experience in virology, clinical development, and regulatory affairs spanning Asia, Europe, and North America. Dr. Xiong most recently served as Director of Regulatory Affairs at InterMune where she was responsible for establishing and managing the product labeling function for European and Canadian commercialization and US labeling preparation for Esbriet NDA for Idiopathic Pulmonary Fibrosis. Previously, she served as Director of China Operations at Covance in Shanghai, responsible for business strategy, client and goverment interactions. Dr. Xiong was at Gilead for 15 years, where she held positions in Clinical Virology and Regulatory Affairs, leading the clinical virology development program for Hepsera for HBV from Phase 2 through product approval. She was involved in multiple IND and NDA filings as well as commercial product labeling for antiviral programs in the US with FDA and in China with CFDA while at Gilead. Dr. Xiong has extensive experience in drug discovery and development in viral diseases including HBV, HCV, HIV, and CMV. She is an author on over 30 publications in scientific journals and publications. Dr. Xiong received her Ph.D. in Biochemistry from University of Wisconsin-Madison and B.S. in Chemistry from Beijing University.
Follow Shelly Xiong:
About Eiger BioPharmaceuticals: Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.
Rebecca Newman
Vice President of External Relations of Salk Institute for Biological Studies
Rebecca Newman joined the Salk Institute as the Vice President, External Relations in February 2008. Since her arrival, the Institute has enjoyed an annual net increase in event profits, a historic fundraising cycle and exciting new experiences with unique events such as Chihuly at the Salk, Step into Discovery, the Salk Science and Music Series and Symphony at Salk. In her oversight of fundraising programs, donor relations, and communications, the Institute’s visibility, awareness and community involvement have developed dramatically. In addition, Ms. Newman has led her team to increase private giving by approximately 40 percent over the last four years. She has overseen Salk’s first major fundraising campaign, with a goal of raising $300 million to support scientific research. Newman brings more than 25 years of financial endowment development and capital campaign experience from the business and nonprofit industries. She joined Salk after serving for seven years at the University of California, San Diego, as Associate Vice Chancellor, Development. In this role, she executed a historic conclusion of UCSD’s capital campaign by exceeding its $1 billion goal. She has a long history of volunteerism in the philanthropic community, serving as national president of the United Jewish Communities and National Chair for the United Jewish Appeal Women’s Campaign. Locally, she was campaign chair and president of the United Jewish Federation of San Diego, and a former board member of the Jewish Community Foundation and the San Diego National Bank Business Advisory Council. As a volunteer, she helped design, fund and implement welfare and relief programs in countries as diverse as Argentina, Cuba, Israel, and the republics of the former Soviet Union. A native of Chicago, Rebecca Newman has a bachelor’s degree in history and political science from the University of Michigan.
Follow Rebecca Newman:
About Salk Institute for Biological Studies: Salk Institute for Biological Studies conducts research on molecular biology and genetics, neurosciences, and plant biology.
Kim Witmer
Senior Vice President & Chief Financial Officer & Treasurer of Salk Institute for Biological Studies
Kim Witmer is Senior Vice President, Chief Financial Officer and Treasurer of the Salk Institute. She oversees all financial activities of the Salk, including financial reporting and treasury functions, research accounting, annual budgets, procurement, grants administration and endowment/investment management. Prior to joining the Salk, Witmer worked for the international accounting firm of Deloitte & Touche. Witmer also acts as past President of AIRI, the Association of Independent Research Institutes, as well as serving on AIRI’s Board of Directors and Government Affairs Committee. AIRI brings together nearly 100 independent, not-for-profit biomedical and behavioral research institutes whose mission is to enhance the ability of its members to improve human health and advance knowledge. Additionally, Witmer served as the Chief Financial Officer and Treasurer of the Sanford Consortium for Regenerative Medicine (SCRM), and currently holds a position on SCRM’s Administrative Council as the Salk representative. She is a Certified Public Accountant and holds a B.S. in business administration from San Diego State University.
Follow Kim Witmer:
About Salk Institute for Biological Studies: Salk Institute for Biological Studies conducts research on molecular biology and genetics, neurosciences, and plant biology.
Jennefer Collins
Vice President of Academic & Administrative Services of Salk Institute for Biological Studies
Jennefer Collins is Vice President of Academic and Administrative Services at the Salk Institute. She is responsible for the education outreach programs, human resources, academic program management including immigration and postdoctoral services, and graduate education affiliate programs, business information systems, and the Salk library. Prior to joining the Salk Institute in 2008, she served in higher education and health care administration, most recently as Assistant Vice Chancellor, Academic Affairs at the University of California, San Diego (UCSD). Additional positions held include Executive Officer, Biological Sciences at UCSD, and Director of Financial Affairs at the University of Southern California (USC), School of Dentistry. Ms. Collins has received many awards and honors, including awards honoring excellence in Academic Program Management at UCSD, and the Associated Student Body Award for Outstanding Service at USC. She has a bachelor’s degree from the University of Southern California.
Follow Jennefer Collins:
About Salk Institute for Biological Studies, University of California, San Diego: Salk Institute for Biological Studies conducts research on molecular biology and genetics, neurosciences, and plant biology.
Stephanie Pinto
Vice President Operations of Noyo
Stephanie Pinto currently works as Vice President of Operations at Noyo.
Follow Stephanie Pinto:
About Noyo: Modern infrastructure for health insurance
Adam Bayaa
Vice President of IT & Security of Heal
Adam is Vice President of IT & Security at Heal, and has over 15 years’ experience in the retail, hospitality and healthcare industries.
Follow Adam Bayaa:
About Heal: Heal is an in-home primary care practice that offers modern doctor house calls, one-touch telemedicine and remote monitoring for seniors.
Mike Jensen
Senior Vice President of Operations of Heal
Follow Mike Jensen:
About Heal: Heal is an in-home primary care practice that offers modern doctor house calls, one-touch telemedicine and remote monitoring for seniors.
Chaz Hinkle
Senior Vice President, Chief People Officer of Welltok
Chaz leads Welltok’s people function, responsible for attracting, developing and engaging a high-impact workforce dedicated to changing the way consumers experience healthcare. Prior to joining Welltok, Chaz served as the Chief Human Capital Officer for Matrix Medical Network, a healthcare services company now part of Providence Service Corporation. Before that, he was a human resources and enterprise services executive at TriZetto Corporation where he focused on organizational effectiveness and leadership development. Chaz also served nearly 10 years in the U.S. Marine Corps achieving the rank of Gunnery Sergeant and completing two tours of duty in Iraq in support of Operation Enduring Freedom and Operation Iraqi Freedom. Chaz holds an MBA from the University of Illinois at Urbana-Champaign, where he also earned his bachelor of science in Finance and Accountancy degrees with highest honors.
Follow Chaz Hinkle:
About Welltok: Welltok is a data-driven, enterprise SaaS company that delivers a healthcare consumer activation platform.
Spencer Sias
Vice President, Corporate Communications and Investor Relations of Varian
Spencer Sias joined Varian Medical Systems in 1999 when it became one of three independent businesses created by the spin-off of Varian Associates, Inc. He manages investor relations and corporate communications including public relations, employee communications and community relations for the company.
Follow Spencer Sias:
About Varian: Varian Medical Systems is a manufacturer of medical devices and software for treating cancer and other medical conditions.
Franco Palomba
Senior Vice President, Finance and Treasurer of Varian
Franco N. Palomba is responsible for domestic and international cash management, foreign exchange activites, derivatives, credit, receivables, and stock administration. He is also responsible for the company’s risk management, tax, fleet, and travel functions. Palomba joined Varian Medical Systems in 2004, after serving as vice president and controller of Varian, Inc. since 1999. From 1984 to 1999, Palomba worked with Varian Associates, Coopers&Lybrand, and PricewaterhouseCoopers, in various audit management positions.
Follow Franco Palomba:
About Varian: Varian Medical Systems is a manufacturer of medical devices and software for treating cancer and other medical conditions.
Patrick Joda
Vice President and General Manager of Varian
Patrick Joda assumed the role of vice president and general manager of Varian’s Oncology Systems Customer Support Services in November 2011. Joda joined the company in 2005, as senior director of Oncology Systems (OS) manufacturing. In 2006, he was promoted to the position of vice president, OS worldwide operations. In 2009, he assumed the responsibility for OS worldwide engineering.
Follow Patrick Joda:
About Varian: Varian Medical Systems is a manufacturer of medical devices and software for treating cancer and other medical conditions.
Susan M. Kanaya
Senior Vice President, Finance, Chief Financial Officer and Secretary of ChemoCentryx
Ms. Susan M. Kanaya has served as our Senior Vice President, Finance, and Chief Financial Officer since January 2006, and Secretary since February 2006. Prior to joining us, Ms. Kanaya served as Senior Vice President, Finance, and Chief Financial Officer at Kosan Biosciences Inc., a biotechnology company, from 1999 to 2005. Prior to this, she served in financial management positions at SUGEN, Inc., a biotechnology company, from 1994 to 1999, most recently as Vice President, Finance, and Treasurer. Ms. Kanaya also served as Controller with high technology companies and as a public accountant with KPMG. Ms. Kanaya received her B.S. in business administration from the University of California, Berkeley.
Follow Susan M. Kanaya:
About ChemoCentryx: ChemoCentryx develops orally administered small molecule therapeutics that target chemokine receptors and related chemo-attractants.
George Winston
Senior Vice President / General Manager Acute Care Division of Sommetrics
33 years in healthcare commerce, including sales, sales management, marketing, marketing management, with Sorenson Research, Abbott Laboratories and Hospira Worldwide and 5i Sciences. This experience spans across several medical device product lines for the hospital critical care, CV surgery, and CV anesthesia markets. The product lines include physiological pressure measurement, continuous mixed venous oxygen saturation monitoring, electronic infusion devices, airway management, sleep apnea and CV Surgery devices. Net result of the assignments is a thorough understanding of the acute care hospital market, with special knowledge of physician and nursing technology needs along with designing and selling products into the anesthesia, critical care and CV surgery areas. Currently V.P. Marketing, 5i Sciences, a medical device start-up with a focus on OSA and airway management in sedated patients, undergoing medical procedures. Experienced in partnership and financial discussions with major potential corporate partners and investors. Areas of experience include: Establishment of a regional critical care sales force with top and bottom line sales accountability, establishment of a KOL referral program, development of sales and product training materials and participation in the product design process, with focus on product usability to enhance clinician acceptability. Education: 1972 – 1975 Florida Atlantic University, Boca Raton, Florida Marketing and business, 1969 – 1971 Miami – Dade College, Miami, Florida A.A.S., Aeronautical Technology. FAA flight certifications include Commercial license, Flight instructor, Instrument flight instructor.
Follow George Winston:
About Adela Health Inc., Keiretsu Forum, Sommetrics, TruPosture: Sommetrics is focused on improving health and well-being by optimizing sleep quality.
Alex Choy
Executive Vice President R&D, CIO of Change Healthcare
Alex Choy is executive vice president of Research and Development and Information Technology and serves as the company’s chief information officer. Before joining Change Healthcare, Mr. Choy was global vice president, Product Development at Oracle Corporation, responsible for all research, development, and delivery of the Oracle healthcare and life sciences product portfolio. Prior to Oracle, Mr. Choy was vice president of Engineering for enterprise software products for Adobe Systems. There he brought in and cultivated an enterprise software culture and product discipline. He also was a key driver of its cloud transformation and key technology acquisitions, leading to the company’s digital marketing platform. Before joining Adobe, Mr. Choy held senior product and engineering positions, including founding team level, at Interwoven, Veritas Software, Tandem, Sun Microsystems, and Hewlett-Packard. Mr. Choy holds a B.S. in computer science from the University of California, Berkeley, and a master’s degree in computer science from Stanford University.
Follow Alex Choy:
About Change Healthcare: Change Healthcare is a healthcare technology company that focuses on accelerating the transformation of the healthcare system.
Aslan Noghre-kar
Vice President of Enterprise Communities of Change Healthcare
Aslan Noghre-kar is the VP of enterprise communities at Change Healthcare.
Follow Aslan Noghre-kar:
About Change Healthcare: Change Healthcare is a healthcare technology company that focuses on accelerating the transformation of the healthcare system.
Nik Tehrani
Vice President of Business Development of Dynosense
Dr. Nik Tehrani earned his PhD in Business Administration from Northcentral University, holds an MBA with a specialization in Executive Management from Pepperdine University and a BS in Electrical Engineering and has over 17 years of teaching experience as a lecturer and professor at various universities in the San Francisco Bay Area. He also has over 8 years of experience advising and mentoring university graduate students, and currently serves as a Dissertation Committee Chair and Member at Argosy University, San Francisco Bay. Dr. Tehrani has taught management, marketing and business courses in Finland, China, Taiwan, Korea, Vietnam, and Chile. Dr. Tehrani has been able to supplement his teaching with professional experiences. Spending over 20 years as a high-level executive for various companies in Silicon Valley has enhanced the body of experiential knowledge he possesses which enables him to pass on practical and theoretical information to his students. As the author of two MBA textbooks, Contemporary Marketing Mix for the Digital Era and Understanding Green Business, he has translated these experiences into applied learning theories. He has published several peer-reviewed academic papers. Please see the publications page for details. Dr. Tehrani has over 25 years of experience in business management, marketing, and supply chain development and implementation. He is currently Vice-President of Business Development for DynoSense Corporation, one of the leaders in emerging advanced remote monitoring of health and preventive care solutions. Prior to DynoSense, he was President and CEO of Savitron, Inc., an Electronic Manufacturing Solution Company; Global Director of Program Management at Sanmina-SCI, a leading EMS provider; Managing Director and Founder of Majital Solutions, a marketing and engineering consulting company; and Vice- President of Marketing and Engineering of ACI, an Electronic Manufacturing Company. Dr. Tehrani is Chair of the Education Committee of the Health Information Management Systems Society (HIMSS), Northern California Chapter, as well as a member of the HIMSS Innovation and Technology Committee. His interests are developing marketing tools for patient engagement, digital health, and enhancing patient experience. Dr. Tehrani is a member of various other prestigious organizations such as the American College of Healthcare Executives; Health Information Management Systems Society (HIMSS); Institute of Electrical and Electronics Engineers (IEEE); United Nations Association of the United States; Commonwealth Club of California; New York Academy of Sciences; American Marketing Association; Higher Education Management Group; Renewable Energy Technology Inventions Group; and Worldwide Management Consultants.
Follow Nik Tehrani:
About Colorado State University, Dynosense, San Jose State University: Dynosense aims to innovate products and services for better life that are integrated, accurate, secure, and simple to use.
Elad Ferber
Vice President and General Manager of ZOLL Medical Corporation
Follow Elad Ferber:
About ZOLL Medical Corporation: ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions.
Brian Stiver
Senior Vice President, Sales & Marketing of Option Care Health
Brian Stiver is the Executive Vice President of Sales and Marketing at Advanced Infusion Solutions (AIS).
Follow Brian Stiver:
About AIS Healthcare, Option Care Health: Option Care Health is a provider of comprehensive, cost-effective pharmaceutical and home care solutions.
Janet Hector
Sr. Vice President of Sales of Drunk Elephant
Follow Janet Hector:
About Drunk Elephant: Drunk Elephant is a non-toxic skin care brand.
Hope Kragh
Vice President, Health Plan Solutions of Amwell
Follow Hope Kragh:
About Amwell: Amwell is a telehealth platform that provides its patients with more affordable, higher quality health care.
Bruce Morimoto
Vice President, Drug Development of Alto Neuroscience
Bruce Morimoto, PhD, brings over 25 years of industry experience in leading project teams in the development of innovative medicines, providing guidance in the design and execution of manufacturing, nonclinical, clinical and regulatory strategies with a therapeutic focus on CNS indications including Parkinson’s, Alzheimer’s and frontotemporal dementias. Previously, Bruce held leadership roles at Cerecin, Alkahest, Celerion and Allon Therapeutics, and works closely as a scientific advisor to the Michael J. Fox Foundation, chairing one of their scientific review panels. Bruce started his career on the faculty in the Chemistry Department at Purdue University, where his independent research focused on neuronal signal transduction. Bruce earned his doctorate in biochemistry from UCLA and completed a postdoctoral fellowship at the University of California Berkeley.
Follow Bruce Morimoto:
About Alto Neuroscience, Cerecin: Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.
Farzad Azimpour
Vice President, Strategic Innovation, Advanced Technology of Edwards Lifesciences
Follow Farzad Azimpour:
About Edwards Lifesciences, Stanford University, Stanford University School of Medicine: Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring.
Chris Masci
Vice President of Business Development of Dedalus Group
Chris Masci joined Dedalus in April of 2014, bringing 9 years of industry experience to the table. Having previously served in key business development positions both in the US and in Europe, Chris oversees all of Dedalus’ business development efforts within the United States. Chris is also responsible for developing Dedalus’s stratetgic partnerships throughout the US healthcare industry. Chris has a B.A. in Finance from Arizona State University.
Follow Chris Masci:
About Dedalus Group: Dedalus Group is a Italian healthcare IT systems company.
Satnam Alag
Senior Vice President Software Engineering and Chief Security Officer of Grail
Dr. Alag is a software professional with over fifteen years of commercial software development and management experience, with over twenty years of experience in machine learning and search areas. His expertise is in Big Data technologies, building large-scale multi-tenant SaaS applications, applying intelligence and personalization to Web 2.0 applications, SOA and J2EE architectures, delivering high-quality software, and building high performing engineering teams. He is currently the CTO and VP of Engineering at NextBio. NextBio is a data-driven engine, which is at the intersection of Big Data and genomics. At NextBio, he leads a team that mines billions and billions of data points using the Hadoop stack and commodity hardware. Prior to joining NextBio, he worked as a consultant with Johnson and Johnson’s BabyCenter where he helped develop their personalization engine. Prior to that, he was the Chief Software Architect and Dir. of Application Engineering at Rearden Commerce. He began his career at GE R&D and has held senior technical and management positions at Computing Technologies International and Black Pearl. Satnam is a Sun Certified Enterprise Architect (SCEA) for the Java platform. His doctoral dissertation from the University of California, Berkeley was in the area of probabilistic reasoning and machine learning. He has a number of peer-reviewed publications, holds five patents. He is the author of the book “Collective Intelligence in Action”.
Follow Satnam Alag:
About Grail, Zenufa Laboratories: Grail develops a pan-cancer screening test designed to detect cancers at an early stage.
Linda Bolton
Senior Vice President & Chief Health Equity Officer of Cedars Sinai Medical Center
Dr. Linda Burnes Bolton is Vice President for Nursing, Chief Nursing Officer, and Director of Nursing Research at Cedars-Sinai. Her research, teaching and clinical expertise includes: nursing and patient care outcomes, improving organization performance, quality care, and cultural diversity within the health professions. She is co-investigator of the regional Collaborative Alliance for Nursing Outcomes research team. Dr. Burnes Bolton is a past president of the American Academy of Nursing and the National Black Nurses Association. She has provided leadership for several state and national programs including service as chair of the National Advisory committee of Transforming Care at the Bedside, Veteran Affairs Commission on Nursing and vice chair of the Robert Wood Johnson Foundation Initiative on the Future of Nursing at the Institute of Medicine. She is a trustee at Case Western Reserve University and a board member of the Robert Wood Johnson Foundation. She was named one of the top 25 women in health care in 2011 by Modern Healthcare magazine. Dr. Burnes Bolton serves on the American Organization of Nurse Executive Board of Directors and will assume the role of President-Elect in 2014. Dr. Burnes Bolton earned her bachelor’s of Science degree in Nursing from Arizona State University (ASU). She completed her master’s of Science degree in Nursing, Master in Public Health, and Doctorate in Public Health from the University of California, Los Angeles (UCLA).
Follow Linda Bolton:
About American Academy of Nursing, Cedars Sinai Medical Center: Cedars-Sinai is a non-profit, academic, community-centric medical center in Los Angeles, California.
Shlomo Melmed
Senior Vice President of Academic Affairs & Dean of the Medical Faculty of Cedars Sinai Medical Center
Shlomo Melmed, MB ChB, MACP, FRCP received his medical degree with distinction from the University of Cape Town, School of Medicine in 1970. At Cedars-Sinai since 1980, he is now Senior Vice-President for Academic Affairs, and Dean of the Medical Faculty. He is also Professor and Associate Dean of the University of California, Los Angeles (UCLA) School of Medicine, and Director of the Research Institute at Cedars-Sinai Medical Center. He holds the Helene A. And Philip E. Hixon Chair in Investigative Medicine. Dr. Melmed is a Diplomate of the American Board of Internal Medicine, certified in Endocrinology and Metabolism; a Master of the American College of Physicians; an elected member of the Association of American Physicians and the American Society of Clinical Investigation; recipient of the Endocrinology Medal of the Royal Society of Medicine; the Endocrine Society Clinical Investigator Award; the Society of Endocrinology Transatlantic Medal; Ipsen Fondation Endocrine Regulation Award; the Pituitary Society’s Lifetime Achievement Award; and is listed in BEST Doctors of America. Dr. Melmed’s laboratory has been consistently funded by the National Institutes of Health (NIH) since 1980, and he has trained over 70 physicians, scientists and graduate students who occupy leading positions in academic endocrinology worldwide. His research is devoted to molecular pathogenesis and treatment of pituitary tumors and growth factor regulation of anterior pituitary function. He has pioneered the discovery and application of novel treatments for endocrine tumors and is a recognized international authority on pituitary medicine. Dr. Melmed is acknowledged as a plenary speaker at multiple national and international meetings and is the author of over 300 peer-reviewed articles in prestigious publications. He edits The Pituitary, co-edits Endocrinology: Basic and Clinical Principles, is the Neuroendocrine Section Editor for DeGroot and Jameson’s Textbook of Endocrinology, and Williams Textbook of Endocrinology; and is pituitary section author for Harrison’s Textbook of Medicine. In addition to being the Editor-in-Chief of Pituitary, he is on the editorial board of Journal of Clinical Investigation and past Editor-in-Chief of Endocrinology. Having served on the NIH Endocrinology Study Section, he also has chaired Special Endocrine Study Sections. He was President and founding member of the Pituitary Society, co-chairs its Program Committee, and was an elected member of the Endocrine Society Council. He was President of the International Society of Endocrinology and a member of the Executive Board Committee, Program Chair of the International Congress of Endocrinology, a Director of the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and is a Board Member of the California Institute of Regenerative Medicine (CIRM). At Cedars-Sinai, Dr. Melmed has spearheaded major academic growth and development by leading building efforts, recruiting talented nationally recognized faculty leadership, establishing new programs and maintaining standards of excellence for educational programs. His executive leadership continues to maintain Cedars-Sinai as a top tier academic medical center.
Follow Shlomo Melmed:
About Cedars Sinai Medical Center, University of California, Los Angeles: Cedars-Sinai is a non-profit, academic, community-centric medical center in Los Angeles, California.
Mike Thompson
Vice President, Enterprise Data Intelligence of Cedars Sinai Medical Center
Vice President, Enterprise Data Intelligence at Cedars-Sinai.
Follow Mike Thompson:
About Cedars Sinai Medical Center: Cedars-Sinai is a non-profit, academic, community-centric medical center in Los Angeles, California.
Richard Jacobs
Senior Vice President of System Development & Chief Strategy Officer of Cedars Sinai Medical Center
Richard B. Jacobs is Senior Vice President of System Development & Chief Strategy Officer at Cedars-Sinai.
Follow Richard Jacobs:
About Cedars Sinai Medical Center: Cedars-Sinai is a non-profit, academic, community-centric medical center in Los Angeles, California.
Jeanne Flores
Senior Vice President of Human Resources & Organization Development of Cedars Sinai Medical Center
Jeanne Flores is Senior Vice President of Human Resources & Organization Development at Cedars-Sinai.
Follow Jeanne Flores:
About Cedars Sinai Medical Center: Cedars-Sinai is a non-profit, academic, community-centric medical center in Los Angeles, California.
Scott Patterson
Vice President, Biomarker Sciences of Gilead Sciences
Scott Patterson, PhD, is Vice President, Biomarker Sciences in the R&D organization at Gilead Sciences, Inc, where he is responsible for development and implementation of biomarker and diagnostic strategies across all the company’s therapeutic areas.
Follow Scott Patterson:
About Gilead Sciences: Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
Kevin Young
Executive Vice President, Commercial Operations of Gilead Sciences
Kevin Young joined Gilead Sciences in 2004 as Executive Vice President of Commercial Operations. Mr. Young is a 29-year veteran of the biopharmaceutical industry, with a career that spans a variety of therapeutic categories including cardiology, oncology, rheumatology, hepatitis and HIV/AIDS. He previously held positions at Amgen, Inc. and AstraZeneca Pharmaceuticals (formerly ICI Pharmaceuticals). During his 12 years at Amgen, Mr. Young held a number of positions in Europe and the United States, most recently as Head of the U.S. Inflammation Business Unit leading the re-launch of Enbrel® following the acquisition of Immunex Corporation. In 2011, Mr. Young was appointed Commander of The British Empire, one of Great Britain’s highest civilian honors, in recognition of his service to the healthcare and pharmaceutical industries. Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise from Liverpool John Moores University and Nottingham University in England and has completed the Executive Program at the University of Michigan.
Follow Kevin Young:
About Gilead Sciences: Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
Ahmed Afifi
Vice President – Region Head Latin America of Gilead Sciences
Follow Ahmed Afifi:
About Gilead Sciences: Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
Remy Durand
Vice President of Frazier Healthcare Partners
Remy joined Frazier Healthcare in 2015 and is a Senior Associate on the Frazier Life Sciences team, focusing on investment identification, due diligence, and deal closing. Prior to joining Frazier Healthcare, Remy was a member of the investment team at GE Ventures and a management consultant in LEK Consulting’s life science practice. Remy has also worked with several start-ups, including Maya Medical (acquired by Covidien) and Northstar Neuroscience. Remy received his Ph.D. in bioengineering from Stanford University, where his doctoral research focused on using optogenetic tools to map neural circuits in the brain and to understand the basis of functional neural imaging. He also holds a B.S.E. degree in biomedical engineering from Case Western Reserve University.
Follow Remy Durand:
About Frazier Healthcare Partners: Frazier Healthcare Partners is a healthcare investment firm for pharmaceuticals, healthcare services, & medical products.
Richard Hope
Vice President of Clinical and Medical Affairs of Ivantis
Richard Hope currently works as Vice President of Clinical & Medical Affairs at Ivantis.
Follow Richard Hope:
About Ivantis: Ivantis is focused on developing an innovative treatment for glaucoma which includes eye drops, laser therapy, and surgery.
Ken Galt
Vice President of Research and Development of Ivantis
Ken Galt currently works as Vice President of Research and Development at Ivantis.
Follow Ken Galt:
About Ivantis: Ivantis is focused on developing an innovative treatment for glaucoma which includes eye drops, laser therapy, and surgery.
Allison Wey
Senior Vice President of Investor Relations and Corporate Communications of Xeris Pharmaceuticals
Ms. Wey serves as Senior Vice President of Investor Relations and Corporate Communications. She brings over 30 years of experience in investor relations, corporate communications, media relations and investment banking to Xeris. Prior to joining Xeris, Ms. Wey served as Vice President, Investor Relations and Corporate Communications at Regulus Therapeutics, Durata Therapeutics and Par Pharmaceuticals. Prior to these positions, Ms. Wey was VP, Investor Relations at Boron, LePore & Associates, Senior Vice President at Edelman Financial Worldwide, Managing Director, Financial Communications at Hill & Knowlton, and Associate Director, Equity Capital Markets at Bear, Stearns & Co. Inc. Ms. Wey is a graduate of Drake University.
Follow Allison Wey:
About Durata Therapeutics, Xeris Pharmaceuticals: Xeris Pharmaceuticals is a pharmaceutical company that develops therapies for patients in endocrinology, neurology, and gastroenterology.
Doug Cassidy
Vice President of Deep 6 AI
Doug Cassidy is the vice president at Deep 6 AI.
Follow Doug Cassidy:
About Deep 6 AI: Deep 6 AI is an AI-based platform that finds patients for clinical trials and it helps to provide cure to people.
Eric Gildenhuys
Vice President and Business Development of Deep 6 AI
Eric Gildenhuys is the vice president in business development at Deep 6 AI.
Follow Eric Gildenhuys:
About Deep 6 AI: Deep 6 AI is an AI-based platform that finds patients for clinical trials and it helps to provide cure to people.
Ryan T Sullivan
Executive Vice President & General Counsel of Anacor Pharmaceutical
Ryan T. Sullivan has served as our Executive Vice President, General Counsel and Secretary since February 2016, after serving as Senior Vice President, General Counsel and Secretary from April 2014 to February 2016. From July 2007 until December 2013, Mr. Sullivan worked as an attorney in the legal group of Warner Chilcott plc, a leading specialty pharmaceutical company that was acquired by Actavis plc for approximately $9 billion. During his tenure, Mr. Sullivan served in a number of positions of increasing responsibility, including most recently as Vice President, General Counsel and Secretary of Warner Chilcott plc. Before joining Warner Chilcott plc, Mr. Sullivan practiced in the New York corporate law group of Cahill Gordon & Reindel LLP. Mr. Sullivan holds a B.S. from Cornell University and a J.D. from Cornell Law School.
Follow Ryan T Sullivan:
About Anacor Pharmaceutical: Anacor Pharmaceutical is a biopharmaceutical company developing small-molecule therapeutics from its boron chemistry platform.
Jacob J. Plattner
Senior Vice President of Research of Anacor Pharmaceutical
Jacob J. Plattner, Ph.D., has served as Anacor’s Senior Vice President, Research since February 2004. From 1998 to 2004, Dr. Plattner was Vice President of Small Molecule Discovery Research at Chiron, a biopharmaceutical company. Prior to joining Chiron, Dr. Plattner held managerial and research positions in chemistry and pharmaceutical research with Abbott Laboratories, a pharmaceutical company, from 1977 to 1998. Dr. Plattner received a B.S. from the University of Illinois and a Ph.D. from the University of California, Berkeley.
Follow Jacob J. Plattner:
About Anacor Pharmaceutical: Anacor Pharmaceutical is a biopharmaceutical company developing small-molecule therapeutics from its boron chemistry platform.
James R. Marconi
Vice President of Finance & Controller of Anacor Pharmaceutical
James R. Marconi has served as Anacor’s Vice President of Finance and Controller since November 2007. From August 2004 to December 2006, Mr. Marconi served as the Vice President of Finance and Chief Accounting Officer for Oncology Therapeutics Network, a leading provider of products and services for community-based oncology practices. From July 1982 to August 2002, Mr. Marconi held various positions of increasing responsibility with DHL Worldwide Express Network, including Financial Reporting Manager, Corporate Controller and, most recently, Vice President and Controller for the U.S. parent company, DHL Holdings (USA), Inc. Before joining DHL, Mr. Marconi was a Senior Auditor for the international public accounting firm, Grant Thornton, CPA’s, LLP. Mr. Marconi received a B.S. in Business Administration/Accounting from the University of California, Berkeley
Follow James R. Marconi:
About Anacor Pharmaceutical: Anacor Pharmaceutical is a biopharmaceutical company developing small-molecule therapeutics from its boron chemistry platform.
Carmen R Rodriguez
Senior Vice President of Regulatory Affairs & Quality of Anacor Pharmaceutical
Follow Carmen R Rodriguez:
About Anacor Pharmaceutical: Anacor Pharmaceutical is a biopharmaceutical company developing small-molecule therapeutics from its boron chemistry platform.
Daniel Simon
Senior Vice President, BioPharma Business Development of Guardant Health
Follow Daniel Simon:
About Guardant Health: Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs in oncology.
Zhongjin Lu
Vice President of Product Development of Arcadia Biosciences
Dr. Lu has 30 years of experience in agronomy, crop genetics and breeding, plant stress physiology, and agricultural biotechnology.Prior to joining Arcadia Biosciences, Dr. Lu was Director of Plant Breeding and Senior Scientist at Seaphire International Inc., a seawater-based agricultural company in Arizona, where he led R & D programs for genetic improvement of Salicornia bigelovii as a halophytic oilcrop grown on coastal deserts irrigated with full-strength seawater. During this time, two salicornia cultivars (cv. SIS 1 and cv. SIS 2) for seawater agriculture were released by the USDA PVP Office, and five elite lines were developed for saline land irrigated with brackish water. Prior to Seaphire International, Dr. Lu was with the Monsanto Company where he was responsible for the project of salicornia genetic improvement for saline agriculture. Through the program, more than two thousand genetic accessions in Salicornia bigelovii collected from the wild in North America were systematically characterized, which served as foundation of the salicornia gene bank. Dr. Lu also spent nearly ten years with the Jiangsu Academy of Agricultural Sciences (JAAS), China and worked in all aspects of Brassica, including genetics, breeding, physiology, agronomy, and product quality. While with JAAS, Dr. Lu developed multiple apetalous OP and hybrid canola lines characteristic of high-yielding, high-oil content and resistance to Sclerotinia diseases. He attained several scientific achievements authenticated and awarded at both provincial and national levels. Dr. Lu is the named inventor on four patents (two in China and two in the U.S.), and is the author of more than 70 peer-reviewed scientific papers and book chapters. Dr. Lu holds an M.S. in Plant Genetics and Breeding from the Nanjing Agricultural University, China and a Ph.D. in Plant Physiology from Technion – Israel Institute of Technology
Follow Zhongjin Lu:
About Arcadia Biosciences: Arcadia Biosciences is an agricultural technology company developing products that benefit the environment and human health.
Don Emlay
Vice President of Regulatory Affairs of Arcadia Biosciences
Mr. Emlay has a total of 39 years of regulatory experience with consumer, industrial and transgenic plant products. While with Zoecon during the period from 1973 to 1987, he worked exclusively with the EPA in obtaining approvals for the first insect growth regulators to be registered for homeowner and pest control applications. For the past 17 years, he has worked exclusively in the plant biotechnology area. As vice president of regulatory affairs with Calgene Inc. from 1987 through 2000, he was active in the initial development of guidance for industry and regulatory agencies for transgenic plants. He led the team of scientists, lawyers and regulatory specialists that brought the first genetically engineered whole food through the USDA and FDA regulatory approval processes. Subsequent to completing the FDA consultation and USDA de-regulation processes for the FLAVR SAVR tomato, he led the completion of the processes for BXN Cotton (tolerant to the herbicide bromoxynil) and Laurate Canola (canola containing a high level of lauric acid). He has extensive experience working with research, product development, marketing, and production groups to ensure planning considers and addresses regulatory requirements. While at Calgene, Mr. Emlay was directly involved with the design and implementation of media and public relations plans associated with transgenic plant products in general and Calgene’s products. He worked with BIO and the International Food Biotechnology Council to guide and shape political and public opinion about transgenic plant products and provides scientific guidance to regulatory agencies. He was active in government relations for Calgene and through BIO. As a consultant beginning in 2000, Mr. Emlay provided guidance to companies developing input trait products and high-value output products. In this role, he provided counsel in the areas of research, product development, production and regulatory procedures to ensure product registerability and acceptance by customers and the public. He worked with all parties involved in the development of a new product to provide the procedures and data required by the FDA to obtain approval of the finished product and by the USDA for commercial growing.
Follow Don Emlay:
About Arcadia Biosciences: Arcadia Biosciences is an agricultural technology company developing products that benefit the environment and human health.
Ryan Kaps
Vice President & GM of EXOS
Ryan Kaps is Founder at Blast Motion.
Follow Ryan Kaps:
About Blast Motion, EXOS: EXOS offers integrated performance training, nutrition, and physical therapy services and solutions for athletes.
Troy McHenry
Executive Vice President, General Counsel and Corporate Secretary of HCPI
Mr. McHenry has been our Executive Vice President, General Counsel and Corporate Secretary since February 2016. He has been with HCP since 2010, most recently as Senior Vice President — Legal, HR and Assistant Corporate Secretary from July 2013 to February 2016. Prior to joining HCP, Mr. McHenry served as Vice President, Deputy General Counsel and Assistant Corporate Secretary at MGM Resorts International (NYSE: MGM). Prior to that, he served as Associate General Counsel at Boyd Gaming Corporation (NYSE: BYD). Mr. McHenry was also a senior associate with the law firm of DLA Piper (formerly Gray Cary). He graduated from the US Military Academy at West Point, received his JD from the University of Southern California (USC) Gould School of Law, and received his MBT from the USC Marshall School of Business/Leventhal School of Accounting. Mr. McHenry also served as an officer (First Lieutenant) in the U.S. Army.
Follow Troy McHenry:
About HCPI: HCPI procures services in Healthcare services and implements in a helpful manner.
John Lu
Executive Vice President — Corporate Finance and Investments of HCPI
John Lu has been our Executive Vice President — Corporate Finance and Investments since January 2016. He has been with HCP since 2006, most recently as Senior Vice President — Financial Planning and Investor Relations from January 2011 to January 2016, and previously served in various roles in acquisitions, investment management and life science. Prior to joining HCP, Mr. Lu spent five years at Merrill Lynch in its investment banking division. He received his BS in Mathematics from Harvey Mudd College and BA in Economics from Claremont McKenna College.
Follow John Lu:
About HCPI, Highland Capital Partners: HCPI procures services in Healthcare services and implements in a helpful manner.
Paul C. Julian
Executive Vice President and Group President of McKesson
Paul C. Julian is executive vice president and group president of McKesson Corporation. He has senior operating responsibility for McKesson’s domestic and international Distribution Solutions businesses, including pharmaceutical distribution, medical-surgical distribution, specialty health and retail pharmacy systems and automation. During his tenure as president of McKesson Pharmaceutical, the company’s largest operating business, McKesson re-gained its position as the largest North American pharmaceutical distributor, rising from the third largest to become the largest wholesaler over a three-year period. Julian oversaw the largest operations and technology upgrade in McKesson’s history, and spearheaded widespread company adoption of Six Sigma. Today, McKesson is often cited for its U.S. corporate productivity leadership. Additionally, he has helped bring new capabilities into the McKesson portfolio including acquisitions in specialty/oncology, pharmaceutical packaging, pharmaceutical and medical-surgical distribution, informatics and in medical products e-commerce. Julian has led many of McKesson’s progressive moves in recent years, including the development of the company’s Health Mart independent retail pharmacy franchise network. He also led the company’s creation of the TogetherRx and Rx Savings Access prescription drug discount cards, both innovative efforts to help seniors save money on their prescription medicines. After joining McKesson in 1996 as executive vice president of McKesson Health Systems, the company’s distribution business for hospitals, Julian went on to become president of McKesson’s medical-surgical business. From 1997-2000, he oversaw a 50 percent increase in medical-surgical distribution revenues and a doubling of operating profit. Also during that time, McKesson signed an unprecedented 20-year distribution agreement with Premier Provider Select for its non-acute care business. Julian became president of McKesson’s distribution, retail automation, pharmacy outsourcing and services for payers in 2000. A highlight of the period to follow was the 2003 decision by the Department of Veterans Affairs to move its pharmaceutical distribution business away from another distributor to McKesson. In 2004, Julian was named to his current position as group president of the corporation. Previously, he held a variety of senior management positions in health care companies, notably Owens & Minor and Stuart Medical, Inc. Within five years, he rose from Stuart Medical, Inc. sales manager to group vice president and chief operating officer. Julian serves on the board of directors of the National Association of Chain Drug Stores and the International Federation of Pharmaceutical Wholesalers (IFPW). He previously served as chairman of the board for the IFPW and the Healthcare Distribution Management Association. He is a 1978 graduate of Salem State College in Massachusetts, where he earned a B.S. degree
Follow Paul C. Julian:
About McKesson: McKesson distributes medical supplies, information technology, and care management products and services.
